Company: HCTI
Filing Date: 2025-11-07
Form Type: PRE 14A
Source: 0001213900-25-107617
Chunk: 9

Company: Healthcare Triangle, Inc.
Filing Date: 2025-11-07
Form: PRE 14A
Chunk 9
---
 of no matter to be presented at our special meeting other than the Nasdaq Proposal.                                 
 If any other matters properly come before our special meeting upon which a vote properly may be taken, shares represented by all    
 proxies received by us on the proxy card will be voted with respect thereto as permitted and in accordance with the judgment of the 
 proxy holders.                                                                                                                      |

| Q. | Will a stockholder list be available for inspection? |

| A. | In accordance with our Bylaws, a list of stockholders entitled                                                                       
 to vote at our special meeting will be available at our special meeting and, for 10 days prior to our special meeting, at Healthcare 
 Triangle, Inc., 7901 Stoneridge Drive, Suite 220, Pleasanton, California 94588. Telephone: (925) 270-4812.                           |

| Q. | Who should I contact if I have any questions 
 about how to vote?                           |

| A. | If you have any questions about how to vote your shares, 
 you may contact Alliance Advisors at (866) 804-9616.     |

<div align='center'>4

NASDAQ APPROVAL PROPOSAL</div>

TO CONSIDER AND VOTE ON A PROPOSAL TO APPROVE, FOR PURPOSES OF NASDAQ LISTING RULE 5635(D), ISSUNCES OF SECURITIES THAT ARE COMPLETED FROM [DATE OF SPECIAL MEETING] UNTIL THREE MONTHS THEREAFTER THAT ARE IN THE AGGREGATE UP TO $[50] MILLION, AS LONG AS EACH FUTURE ISSUNACE IS WITHIN THE NASDAQ PARAMETERS (AS DEFINED BELOW).

Our stockholders are being asked to approve at
the Special Meeting, for purposes of Nasdaq Listing Rule 5635(d), issuances of the Company’s securities that are completed
from and after [the date of the Special Meeting] until three months thereafter that are in the aggregate up to $[50] million (“Future
Issuances”), as long as each Future Issuance is within the Nasdaq Parameters (as defined below).

Pursuant to Nasdaq Listing Rule 5635(d),
stockholder approval is required prior to a 20% Issuance at a price that is less than the Minimum Price. For purposes of Nasdaq Listing
Rule 5635(d), (i) “20% Issuance” means a transaction, other than a public offering, involving the sale, issuance
or potential issuance